주요 FierceBiotech 2026년 4월 20일 Agenus focuses on survival data as 0% response rate triggers primary miss Agenus focuses on survival data as 0% response rate triggers primary miss 열기 관련 신호 FierceBiotech 2026년 4월 20일 Odyssey charts fresh voyage to public markets after abandoning IPO plans last year FierceBiotech 2026년 4월 20일 AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win FierceBiotech 2026년 4월 20일 How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients